<DOC>
	<DOCNO>NCT00814086</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cisplatin give together paclitaxel treat patient stage IIB , stage IIC , stage III , stage IV ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer . Drugs use chemotherapy , cisplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give different way may kill tumor cell .</brief_summary>
	<brief_title>Cisplatin Paclitaxel Treating Patients With Stage IIB , Stage IIC , Stage III , Stage IV Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine feasibility intraperitoneal ( IP ) cisplatin intravenous ( IV ) paclitaxel follow IP paclitaxel patient stage IIB , IIC , III , IV ovarian epithelial , fallopian tube , primary peritoneal cavity cancer . SECONDARY OBJECTIVES : I. Assess toxicity regimen patient . II . Determine type surgical catheter complication may occur surgery course treatment patient . III . Estimate response rate patient measurable disease treat regimen . OUTLINE : This multicenter study . Patients receive paclitaxel IV 3 hour cisplatin intraperitoneally ( IP ) day 1 paclitaxel IP day 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cavity cancer Stage IIB , IIC , III , IV disease Optimal suboptimal residual disease debulking surgery within past 12 week Appropriate tissue histologic evaluation available The following histologic epithelial cell type eligible : Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner tumor Adenocarcinoma otherwise specify Carcinosarcoma No ovarian epithelial carcinoma low malignant potential ( borderline carcinoma ) No synchronous primary endometrial cancer history primary endometrial cancer unless follow condition meet : Stage ≤ IB disease No superficial myometrial invasion , without vascular lymphatic invasion No poorly differentiate subtypes , include papillary serous , clear cell , FIGO grade 3 lesion GOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN SGOT ≤ 2.5 time ULN Audiograms require study chemotherapy course 3 6 patient hearing loss , experience tinnitus study therapy Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception None follow : Septicemia Severe infection require parenteral antibiotic Malnutrition require parenteral hyperalimentation Acute hepatitis Any major medical condition expect interfere completion protocol therapy No active bleeding No circumstance would prohibit completion study therapy require followup No history allergic reaction polysorbate 80 ( e.g. , etoposide vitamin E ) No invasive malignancy , except nonmelanoma skin cancer specific malignancy within past 5 year , whose previous cancer treatment contraindicate protocol therapy No unstable angina myocardial infarction within past 6 month Abnormal cardiac conduction ( e.g. , bundle branch block heart block ) stable past 6 month allow No prior target therapy management ovarian epithelial primary peritoneal cavity cancer include , limited , follow : Vaccines Antibodies Tyrosine kinase inhibitors No prior chemotherapy No prior radiotherapy No prior hormonal therapy management epithelial ovarian primary peritoneal cavity cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>